Shots:
- Health Canada has approved Vyvgart (efgartigimod alfa; QW, SC, PFS) as a monotx. for adults with chronic inflammatory demyelinating polyneuropathy (CIDP)
- Approval was based on the ADHERE trial, showing 69% (221/322) of Vyvgart SC-treated pts had clinical improvement, regardless of prior treatment. The study met its 1EP with a 61% reduction in relapse risk vs PBO, with ~99% pts joining the OLE study
- Efgartigimod SC is an IgG1 antibody fragment that reduces circulating IgG autoantibodies by binding to the neonatal Fc receptor (FcRn)
Ref: Newswire.CA| Image: Argenx | Press Release
Related News:- argenx Reports Topline P-III (ADAPT SERON) Trial Data of Vyvgart for AChR-Ab Seronegative Generalized Myasthenia Gravis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
